Global transcatheter (percutaneous) mitral valve market was valued at US $ XX Mn and expected to grow at XX% Compound Annual Growth Rate (CAGR) over the 2018 to 2024.

Market Outline: Transcatheter (percutaneous) Mitral Valve Market

Transcatheter (percutaneous) mitral valve is used to treat mitral regurgitation (MR). Mitral valve disease is the second most common valvular heart disease in adults. MR is classified as either primary (degenerative) or secondary (functional). Primary MR from degenerative valve disease is due to a primary disruption of the mitral valve apparatus from either prolapsed or flail leaflets. Secondary MR on the other hand is due to remodeling of the left ventricle resulting inappropriate coaptation of the mitral leaflets. Trans catheter heart valve implantation procedure helps in replacing the heart valve with prosthetic valve for treatment of severe aortic stenosis and mitral regurgitation. This increases survival rate of patients and helps in reducing severe degenerative aortic stenosis.

Market Dynamics: Transcatheter (percutaneous) Mitral Valve Market

Increase in the prevalence of cardiac disorders and increasing aging population are expected to drive the market. The increasing demand for less invasive procedure for high risk patients, severe aortic stenosis disorder and growing prevalence of mitral regurgitation are expected to drive the growth of Transcatheter (percutaneous) mitral valve market. Furthermore, conditions like speedy recovery, shorter span of time required for the patient to stay in the hospital are favoring the implantation of the transcatheter (percutaneous) mitral valve implantation. However, the high costs of the transcatheter heart valves, risk involved in the procedure such as improper positioning of the implant and device related issues such as product recalls by the manufacturers are expected to hamper the growth of transcatheter (percutaneous) mitral valve market.

Geographically, global transcatheter (percutaneous) mitral valve market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America transcatheter (percutaneous) mitral valve market is growing at unprecedented rate due to increase in the prevalence of cardiacdisorders andincreasing incidences of mitral valve disorders.The increasing geriatric population, high number of cases of congenital heart defects which is driving the growth of the transcatheter (percutaneous) mitral valve market in this region. The improving technological advancements and rising government funds are expected to drive the market in Europe. Furthermore, in emerging countries of Asia, increasing focus on investigational product and awareness about the treatment procedures among the patient pool is driving the transcatheter (percutaneous) mitral valve market in this region.

ØIn Feburary 2018, Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, has announced that it has received CE Mark for its self-expanding CENTERA valve for severe, symptomatic aortic stenosis patients at high risk of open-heart surgery.

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.